Interleukin 1 receptor, type II

Transcenta Presented Two Scientific Posters at SITC 2022 Annual Meeting

Retrieved on: 
Friday, November 11, 2022
China Media Group Headquarters, Transforming growth factor beta, DLT, Prevalence, Team Impulse, Nature, Mab, Syngenic, PK, Toxic epidermal necrolysis, Annual general meeting, Process, Immunotherapy, Research, Fucose, FIH, FCR, Adenocarcinoma, Neoplasm, TGF, Environment, Diagnosis, Primate, CDC, Cancer immunotherapy, HKEX, Interleukin 1 receptor, type II, PD-L1, News, Immunoglobulin G, Safety, IHC, PD-1, ICB, SITC, Social conditioning, Society for Immunotherapy of Cancer, Suzhou Industrial Park, Stomach, NK, Patient, Immune system, ADCC, Discovery, Therapy, FDA, Headquarters, Pharmaceutical industry, Vaccine, Medical imaging

SUZHOU, China, Nov. 10, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has presented two scientific posters at the 37th Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston, MA, November 8-12, 2022.

Key Points: 
  • SUZHOU, China, Nov. 10, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has presented two scientific posters at the 37th Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston, MA, November 8-12, 2022.
  • Claudin18.2 staining in 10% of the tumor cells at 1+ or above intensity was present in 216 (72%) tissue samples tested.
  • As of Aug 24, 2022, the first three dose cohorts have been completed and no DLT was observed.
  • Transcenta (HKEX: 06628) is a clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing.

Transcenta to Present Two Scientific Posters at SITC 2022 Annual Meeting

Retrieved on: 
Friday, October 14, 2022
News, CDC, Interleukin 1 receptor, type II, Therapy, Syngenic, Cancer immunotherapy, Science, SITC, FIH, China Media Group Headquarters, Primate, ICB, HKEX, Neoplasm, Patient, Social conditioning, Research, Fucose, Annual general meeting, Immunotherapy, Society for Immunotherapy of Cancer, Cancer, Process, FCR, Immune system, Discovery, Nature, 2021 Essex County Council election, Toxic epidermal necrolysis, EST, ADCC, Environment, NK, PK, Headquarters, PD-L1, FDA, Suzhou Industrial Park, Pharmaceutical industry, Vaccine

Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word "cure" a reality for cancer patients everywhere.

Key Points: 
  • Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word "cure" a reality for cancer patients everywhere.
  • Details of the poster presentations are as follows:
    Full text of the abstracts will be released on the SITC website at 8:00 a.m. EST, November 7, 2022, and the posters will be available on Transcenta's website ( https://www.transcenta.com/ ) on November 12, 2022.
  • Transcenta (HKEX: 06628) is a clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing.
  • Transcenta is developing ten therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders.